Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s
Article Title: Pfizer Has a VEGF Bispecific Strategy that Diverges from Summit’s Publication Date: September 12, 2025 As Wall Street grapples with the disheartening outcomes of Summit Therapeutics’ PD-1xVEGF bispecific cancer drug trial, it’s competitor Pfizer appears well-positioned for advantage.…